This product is a whole gastrointestinal tract motility drug, which can enhance esophageal peristalsis and lower esophageal sphincter tension, prevent gastric contents from reflux into the esophagus, and improve esophageal clearance; increase gastric and duodenal contractility and coordination of gastric antrum and duodenum; reduce duodenal and gastric reflux, improve gastric and duodenal emptying; strengthen intestinal movement and promote small and large intestine transit. This product does not increase the basal and pentagastrin-induced gastric acid secretion. In addition, it has almost no effect on plasma prolactin levels.

It acetylates the cyclooxygenase of platelets, thereby inhibiting the release reaction of platelets, reducing the adhesion rate of platelets, and preventing thrombosis.

It has a strong dilating effect on coronary blood vessels, significantly enhancing coronary flow and myocardial oxygen supply. It can also inhibit platelet aggregation and prevent thrombosis.

It is highly sensitive to some Staphylococci, Streptococcus mutans, Streptococcus salivarius, Candida albicans, Escherichia coli and anaerobic propionibacterium; moderately sensitive to Haemophilus Streptococcus, and lowly sensitive to Proteus, Pseudomonas, Klebsiella and Gram-negative cocci (such as Veillonella). Its antibacterial effect on Gram-positive and Gram-negative bacteria is stronger than that of disinfectants such as Sanisol. It is still effective even in the presence of serum, blood, etc.

Synthetic nucleoside antiviral drugs, which have inhibitory effects on herpes simplex virus type Ⅰ (HSV-1), type Ⅱ (HSV-2) and varicella-zoster virus (VZV) in vivo and in vitro. It terminates herpes virus DNA replication by competitively inhibiting viral DNA polymerase, entering and terminating viral DNA chains, and inactivating viral DNA polymerase.